Please ensure Javascript is enabled for purposes of website accessibility

Why KalVista Pharmaceuticals Stock Skyrocketed 115% Today

By Joe Tenebruso - Feb 9, 2021 at 9:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Analysts say the biotech's investors could be in store for even more gains.

What happened

Shares of KalVista Pharmaceuticals (KALV 0.22%) soared 115% on Tuesday after the pharmaceutical company released promising results from its phase 2 clinical trial for KVD900, its oral drug for hereditary angioedema (HAE) attacks. 

So what 

KalVista's study showed that 15% of the patients who were treated with KVD900 within one hour of experiencing a swelling attack required rescue medication, compared to 30% of those who received a placebo. KVD900 also appeared to be generally safe and well-tolerated, with no serious adverse events reported.

A person points to an upwardly sloping line.

KalVista Pharmaceuticals' stock price surged on Tuesday. Image source: Getty Images.

KalVista CEO Andrew Crockett said KVD900 is the first oral drug to demonstrate results comparable to injectable therapies. "The rapid onset of symptom relief and significant reduction in the use of rescue medication show that patients can confidently take KVD900 at the earliest signs of an attack and avoid the burden and discomfort of injections," Crockett said in a press release. "We look forward to working with regulatory agencies to bring the many advantages of KVD900 to patients as quickly as possible."

Now what 

These results prompted Stifel analyst Paul Matteis to boost his price forecast for KalVista's stock from $30 to $54. Matteis highlighted KVD900's "injectible-like" effectiveness and easier oral administration, which he believes could give it an edge over existing HAE treatments. Matteis's new target price represents potential gains to investors of roughly 61% from KalVista's closing price of $33.50 on Tuesday. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

KalVista Pharmaceuticals, Inc. Stock Quote
KalVista Pharmaceuticals, Inc.
$9.20 (0.22%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.